The CEO of SA’s second-largest generic drug manufacturer sought to allay fears that the government’s drive for universal health coverage poses a risk to the pharmaceutical sector, saying the reforms proposed under the National Health Insurance (NHI) Bill could boost drug sales.

Adcock Ingram CEO Andy Hall’s view is in contrast to the negative investor sentiment that greeted the August 8 release of the bill. The first piece of proposed legislation for the government’s planned health sector reforms saw R14bn wiped off the value of key health-care stocks in the space of three days.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now